Private Equity in Healthcare: What Every Owner Should Know Before Selling

Private equity has been the dominant force in healthcare M&A for more than a decade. Understanding how these buyers think — what they are looking for, how they structure deals, and what happens after closing — is essential for any healthcare owner considering a sale.

Private equity loves healthcare for reasons that have not changed. The sector is large, fragmented, defensive across economic cycles, and structurally growing with demographics. Recurring revenue is common. Regulatory complexity creates barriers to entry. Consolidation opportunities are abundant. And exit multiples for scaled platforms have historically been strong enough to underwrite attractive returns.

The most important distinction in private equity healthcare is between platform and add-on acquisitions. A platform is the first substantial investment a PE firm makes in a subsector — typically a $5M–30M EBITDA company with strong management, clean operations, and a footprint that can be built upon. Platforms command premium multiples because the buyer is paying for a foundation, not just cash flow. Add-ons are subsequent acquisitions rolled into the platform, typically smaller and priced at lower multiples that reflect the integration work required. Understanding which role your company plays in a buyer's thesis dramatically affects the price they will pay.

Roll-ups — the strategy of aggregating many small businesses into a single scaled operator — have been particularly prominent in dermatology, dental, ophthalmology, veterinary medicine, behavioral health, and home care. If your business fits a roll-up thesis, you may have multiple buyers competing for the same asset, and the terms available to you may be materially better than a standalone process would suggest.

Recapitalizations are an alternative to full sales. In a recap, the owner sells a majority (or sometimes minority) interest to a PE firm, retains meaningful equity, and continues operating the business with capital to accelerate growth. Recaps are attractive for owners who are not ready to fully exit, want a second bite at the apple when the platform sells, and are comfortable with an institutional partner in the business.

Minority investments are less common in healthcare but do occur, particularly in growth-stage healthcare IT and services businesses. Minority capital typically comes with governance rights, board representation, and eventual liquidity expectations, but leaves operational control with the founder.

Equity rollover is a common feature of both platform and add-on deals. Sellers reinvest a portion of proceeds — typically 10–30% — into the equity of the acquiring platform. This aligns interests, gives the seller upside if the platform is ultimately sold at a higher multiple, and is often tax-efficient. Rollover terms are heavily negotiated: governance, information rights, drag-along and tag-along provisions, and put/call mechanics all matter.

Life after closing depends on the deal you signed. In most PE transactions, the seller remains involved for a transition period — anywhere from six months to several years — with a clear scope of responsibilities and a defined path to reduced involvement. Cultural integration is real: reporting cadences, financial discipline, and governance expectations tighten under institutional ownership. The best PE partners bring capital, playbooks, and relationships that accelerate growth. The worst bring financial engineering without operational value.

In behavioral health, home care, urgent care, multi-site physician groups, RCM, and healthcare IT, private equity is currently the most active buyer group. Understanding how they operate — before you meet them — is a meaningful advantage at the negotiating table.